AUTH:"Blumenschein GR" - Search results

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

Zhou N, Leung CH, William WN, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, [...] Cascone T

J Immunother Cancer, 12(10):e009677, 23 Oct 2024

Cited by: 0 articles | PMID: 39448200 | PMCID: PMC11499765

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, [...] Heymach JV

Nature, 635(8038):462-471, 09 Oct 2024

Cited by: 0 articles | PMID: 39385035 | PMCID: PMC11560846

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, [...] Nurieva R

Nat Commun, 15(1):5621, 04 Jul 2024

Cited by: 0 articles | PMID: 38965214 | PMCID: PMC11224259

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients.

Wang T, Navenot JM, Rafail S, Kurtis C, Carroll M, Van Kerckhoven M, Van Rossom S, Schats K, Avraam K, Broad R, Howe K, Liddle A, Clayton A, Wang R, Quinn L, Sanderson JP, McAlpine C, Carozza C, Pimpinella E, [...] Blumenschein GR

Mol Ther Methods Clin Dev, 32(2):101265, 14 May 2024

Cited by: 1 article | PMID: 38872830

Add to export list

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.

Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD

Cancer Res Commun, 3(10):2074-2081, 01 Oct 2023

Cited by: 0 articles | PMID: 37728512 | PMCID: PMC10566451

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, [...] Moore PA

Nat Med, 29(11):2814-2824, 19 Oct 2023

Cited by: 23 articles | PMID: 37857711 | PMCID: PMC10667103

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.

Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, [...] Li J

J Immunother Cancer, 11(7):e006871, 01 Jul 2023

Cited by: 4 articles | PMID: 37402581 | PMCID: PMC10335483

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, [...] Skoulidis F

Cancer Discov, 13(7):1556-1571, 01 Jul 2023

Cited by: 37 articles | PMID: 37068173

Add to export list

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.

Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing A

Cancer, 129(17):2685-2693, 02 May 2023

Cited by: 0 articles | PMID: 37129197

Add to export list

Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.

Molife C, Brnabic A, Stefaniak VJ, Belger MA, Gruver K, Chen JV, Souri S, Blumenschein GR

Immunotherapy, 15(4):293-309, 07 Feb 2023

Cited by: 1 article | PMID: 36748406

Add to export list Review

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.

Villaruz LC, Blumenschein GR, Otterson GA, Leal TA

Cancer, 129(9):1319-1350, 27 Feb 2023

Cited by: 4 articles | PMID: 36848319 | PMCID: PMC11234508

Add to export list Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Autologous T cell therapy for MAGE-A4⁺ solid cancers in HLA-A*02⁺ patients: a phase 1 trial.

Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR, Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, [...] Butler MO

Nat Med, 29(1):104-114, 09 Jan 2023

Cited by: 44 articles | PMID: 36624315 | PMCID: PMC9873554

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC.

Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP, Blumenschein GR, Tu J, Altan M, Lee P, Liao Z, Lin SH

JTO Clin Res Rep, 3(9):100391, 07 Aug 2022

Cited by: 15 articles | PMID: 36089921 | PMCID: PMC9449658

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, [...] Nurieva R

Nat Commun, 13(1):1970, 12 Apr 2022

Cited by: 39 articles | PMID: 35413951 | PMCID: PMC9005525

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer.

Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Doger de Spéville B, Frigault MJ, Olszanski AJ, Lam VK, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, [...] Fracasso PM

J Immunother Cancer, 10(1):e003581, 01 Jan 2022

Cited by: 20 articles | PMID: 35086946 | PMCID: PMC8796260

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.

Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR

Cancer Treat Res Commun, 30:100514, 07 Jan 2022

Cited by: 4 articles | PMID: 35051703 | PMCID: PMC9259763

Add to export list Free full text in Europe PMC

Phase II Trial of High-Dose Radiotherapy vs. Low-Dose Radiation, Demonstrating Low-Dose Mediated Immune-Cell Infiltration.

He K, Patel RR, Barsoumian HB, Chang JY, Tang C, Comeaux NI, Ning MS, Gandhi S, Davies M, Glitza I, Hong DS, Heymach J, Nguyen QN, Diab A, Chun SG, Lee P, Blumenschein GR, Fossella FV, Chen D, Welsh JW

Int J Radiat Oncol Biol Phys, 111(3s):S118, 01 Nov 2021

Cited by: 0 articles | PMID: 34700428

Add to export list

Phase II Clinical Trial Evaluating Complete Metastasis Ablation After Progression on Checkpoint Inhibition.

He K, Comeaux NI, Tang C, Ning MS, Hong DS, Heymach J, Nguyen QN, Chang JY, Gandhi S, Diab A, Blumenschein GR, Glitza I, Chun SG, Lee P, Fossella FV, Welsh JW

Int J Radiat Oncol Biol Phys, 111(3s):e471-e472, 01 Nov 2021

Cited by: 0 articles | PMID: 34701533

Add to export list

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.

Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV

JCO Precis Oncol, 5:PO.20.00532, 05 Aug 2021

Cited by: 10 articles | PMID: 34377884 | PMCID: PMC8345916

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck.

Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND

Head Neck, 43(5):1592-1603, 01 Feb 2021

Cited by: 1 article | PMID: 33522021

Add to export list

The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials.

Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S

Clin Radiol, 76(2):155.e25-155.e34, 22 Oct 2020

Cited by: 4 articles | PMID: 33268083

Add to export list

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.

Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, [...] Subbiah V

ESMO Open, 5(5):e000799, 01 Oct 2020

Cited by: 31 articles | PMID: 33097651 | PMCID: PMC7590373

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.

Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, [...] Zhang J

J Thorac Oncol, 15(9):1449-1459, 08 May 2020

Cited by: 86 articles | PMID: 32389639

Add to export list

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.

Hassan R, Blumenschein GR, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC

J Clin Oncol, 38(16):1824-1835, 26 Mar 2020

Cited by: 76 articles | PMID: 32213105 | PMCID: PMC7255978

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.

Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ, Choy H

J Clin Oncol, 38(7):706-714, 16 Dec 2019

Cited by: 192 articles | PMID: 31841363 | PMCID: PMC7048161

Add to export list Free full text in Europe PMC

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients.

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.

Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.

Autologous T cell therapy for MAGE-A4⁺ solid cancers in HLA-A*02⁺ patients: a phase 1 trial.

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC.

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer.

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.

Phase II Trial of High-Dose Radiotherapy vs. Low-Dose Radiation, Demonstrating Low-Dose Mediated Immune-Cell Infiltration.

Phase II Clinical Trial Evaluating Complete Metastasis Ablation After Progression on Checkpoint Inhibition.

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.

Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck.

The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials.

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.

Partnerships & funding